Michelle C. Miller
University of Minnesota(US)Janssen (United States)(US)
Publications by Year
Research Areas
Advanced Breast Cancer Therapies, Galectins and Cancer Biology, Glycosylation and Glycoproteins Research, HER2/EGFR in Cancer Research, Toxin Mechanisms and Immunotoxins
Most-Cited Works
- → Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer(2016)1,957 cited
- → Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3(2018)1,086 cited
- → Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1(2020)570 cited
- → Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer(2019)407 cited
- → Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open‐label clinical trial(2010)237 cited
- → Chemokines from a Structural Perspective(2017)226 cited
- → Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer(2020)177 cited
- → Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study(2016)132 cited
- → Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding(2012)130 cited
- → Galectins as Molecular Targets for Therapeutic Intervention(2018)123 cited